Merck and MD Anderson announce immuno-oncology research collaboration in solid tumors
Clinical trials to evaluate Merck’s KEYTRUDA® (pembrolizumab) in combination with other medicines and treatments across multiple tumor types
MD Anderson News Release 08/13/2015
Merck and Â鶹ӳ» MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination with other treatments, such as chemotherapy,...
MD Anderson names Valerae O. Lewis, M.D., chair of Orthopaedic Oncology
Dr. Lewis is internationally recognized for her expertise in pelvic sarcoma surgery and substantial contributions in shaping orthopaedic education...
Shorter course of radiation therapy associated with less toxicity, improved quality of life in women with early stage breast cancer
MD Anderson researchers recommend hypofractionated treatment as a starting point for treatment discussion between patients, physicians...
Potential new therapy approaches to reverse kidney damage identified
Study shows that cell plasticity program resulting from kidney damage can be targeted to reverse disease and fibrosis.
MD Anderson News Release 08/03/2015
Adults who are worried or terrified sometimes curl up into a fetal position. Likewise, adult cells that are injured, including genetic injury leading to cancer, initiate a process that was present during embryonic development.
Most organs revert to methods...
MD Anderson study reveals new insight into DNA Repair
The enzyme fumarase key to reversing genetic damage leading to cancer and therapy resistance
MD Anderson News Release 08/03/2015<...